Echocardiogram signs that predict outcomes for people hospitalized with worsening heart failure
Early Transthoracic Echocardiographic Predictors of Recurrent Hospitalization and Survival in Patients Hospitalized Due to Decompensated Heart Failure
We will try to see if echocardiogram measurements taken at hospital admission before IV diuretics can predict short- and long-term outcomes for adults hospitalized with acute decompensated heart failure.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 76 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Istanbul University - Cerrahpasa Academic / other |
| Locations | 1 site (Istanbul) |
| Trial ID | NCT07439159 on ClinicalTrials.gov |
What this trial studies
This is a prospective, single-center observational project at Istanbul University-Cerrahpaşa Cardiology Institute enrolling adults admitted with acute decompensated heart failure. Detailed transthoracic echocardiography will be performed at admission before the first intravenous diuretic dose to capture left- and right-heart structural and functional parameters, including measures related to RV–PA coupling. Clinical data, comorbidities, and vital signs will be recorded and linked to short- and longer-term clinical outcomes. An a priori power calculation determined a target enrollment of at least 76 patients, with enrollment planned between December 2024 and December 2025.
Who should consider this trial
Good fit: Adults aged 18 or older who are hospitalized for acute decompensated heart failure, judged to need intravenous diuretics, with predominant left-sided heart failure and able to give written informed consent are ideal candidates.
Not a fit: Patients with primary right heart failure, severe primary valvular disease, those on dialysis or listed for kidney transplant, active malignancy, or who cannot undergo timely transthoracic echocardiography are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, the findings could help clinicians identify higher-risk patients on admission and guide earlier, more personalized treatment decisions.
How similar studies have performed: Previous research has shown many echocardiographic measures predict outcomes in heart failure, but using detailed pre‑diuretic admission parameters and RV–PA coupling in this exact setting is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged ≥18 years. * Hospitalization due to acute decompensated heart failure. * Intravenous diuretic therapy deemed necessary by the treating cardiologist. * Predominant left-sided heart failure. * Provision of written informed consent prior to participation. Exclusion Criteria: * Severe anemia (hemoglobin \<7 g/dL). * Requirement for renal replacement therapy, including hemodialysis or peritoneal dialysis, or being listed for kidney transplantation. * Severe primary mitral regurgitation. * Severe aortic stenosis. * Severe aortic regurgitation. * Severe primary tricuspid regurgitation. * Primary right heart failure. * Heart failure secondary to congenital heart disease. * History of mitral valve replacement. * History of aortic valve replacement. * History of bioprosthetic valve replacement. * History of transcatheter aortic valve implantation. * Presence of active malignancy. * Failure to provide written informed consent. * Inability to perform transthoracic echocardiography prior to intravenous diuretic therapy for any reason.
Where this trial is running
Istanbul
- Istanbul University Cerrahpaşa Institute of Cardiology — Istanbul, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Aybike G Taşdelen Acar, MD
- Email: aybikegul.tasdelen@iuc.edu.tr
- Phone: +905356955610
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.